DreaMed Diabetes · raw details

Founded in 2014, DreaMed pioneered the first artificial pancreas technology. Since then, DreaMed has dedicated itself to developing decision-support tools in the diabetes management field. We are the world’s first and only company to receive FDA clearance for a decision support system that utilizes data from CGM/SMBG (continuous glucose monitoring/self-monitoring of blood glucose) and insulin pumps.

DreaMed's mission is to unlock and scale medical knowledge so that every person living with diabetes can access personalized, expert-level care when and where it’s needed. We strive to achieve this mission by creating software that uses advanced AI and analytics to transform the massive amounts of patient data available into expert-level treatment recommendations, and to do this at a global scale. DreaMed’s product, endo.digital, is a cloud-based SAAS platform that gives healthcare organizations an end-to-end diabetes care pathway solution that can be deployed across all care settings where patients with diabetes are treated, both remotely and in person. It is the only decision support software cleared by the FDA to support both Type 1 and Type 2 diabetes.

DreaMed's founders are physicians and engineers. Our products are developed based on real insights from the clinical practice of diabetes specialists, physicians, and clinical researchers from the top diabetes centers worldwide. We prioritize privacy, security, quality, and regulatory compliance, operating under a stringent quality management system and adhering to ISO 27001, GDPR, and HIPAA standards.